Clinical Proof-of-concept of a Novel Platform Utilizing Biopsy-derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4).
Albala, David, Michael S Manak, Jonathan S Varsanik, Hani H Rashid, Vladimir Mouraviev, Stephen M Zappala, Ene Ette, et al. 2019. “Clinical Proof-of-Concept of a Novel Platform Utilizing Biopsy-Derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4).”. Urology 124: 198-206.